共 50 条
- [3] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (06): : 1221 - 1231
- [4] Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2526 - 2534
- [8] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial (vol 23, pg 1221, 2021) [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (11): : 2600 - 2600